The effects of concanavalin A on the early events of infection by rhinovirus type 2 and poliovirus type 2.
The effect of concanavalin A (Con A) on the course of early infection of HeLa cells with purified radioactive human rhinovirus type 2 (HRV-2) or poliovirus type 2 (P-2) has been examined. Several early steps in infection were inhibited before the uncoating of parental virus. Con A, at 100 mug/ml, reduces attachment of virus when added to cells before infection. Con A also detectably slows the normal progression of adsorbed virus to tightly bound forms characterized, in the case of HRV-2, by resistance to elution by EDTA, or in a case of P-2, by isolation of a characteristic virus-membrane complex. When Con A is added together with either virus, it also inhibits cell-mediated eclipse of infectivity and the formation of non-infective subviral particles.
D000327:Adsorption; D003208:Concanavalin A / Q000494:pharmacology*; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004492:Edetic Acid / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D008766:Methylmannosides / Q000494:pharmacology; D017955:Poliovirus / Q000187:drug effects / Q000254:growth & development*; D012229:Rhinovirus / Q000187:drug effects / Q000254:growth & development*; D014779:Virus Replication / Q000187:drug effects
D008766:Methylmannosides; D003208:Concanavalin A; D004492:Edetic Acid